Neurontin and Parathyroid tumor benign - a phase IV clinical study of FDA data

Summary:

Parathyroid tumor benign is reported as a side effect among people who take Neurontin (gabapentin), especially for people who are female, 30-39 old, also take Zometa, and have Osteoporosis.

The phase IV clinical study analyzes which people have Parathyroid tumor benign when taking Neurontin. It is created by eHealthMe based on reports of 103,969 people who have side effects when taking Neurontin from the FDA, and is updated regularly.

What is Neurontin?

Neurontin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 107,468 Neurontin users. Check the latest studies of Neurontin.

What is Parathyroid tumor benign?

Parathyroid tumor benign is found to be associated with 164 drugs and 230 conditions by eHealthMe. Check the latest studies of Parathyroid tumor benign.

On Jul, 08, 2026

103,969 people reported to have side effects when taking Neurontin.
Among them, 33 people (0.03%) have Parathyroid tumor benign.

Could Neurontin cause Parathyroid tumor benign?

Among these 33 people:

What is the gender of people who have Parathyroid tumor benign when taking Neurontin? *

female: 56.25 %
male: 43.75 %

What is the age of people who have Parathyroid tumor benign when taking Neurontin? *

What are other drugs people take besides Neurontin? *

What are other side effects people have besides Parathyroid tumor benign? *

Infection: 31 people, 93.94%
Osteopenia (a condition where bone mineral density is lower than normal): 31 people, 93.94%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 31 people, 93.94%
Depression: 31 people, 93.94%
Bone Disorder: 31 people, 93.94%
Acute Kidney Failure: 30 people, 90.91%
Pain In Extremity: 30 people, 90.91%
Bone Pain: 30 people, 90.91%
Abdominal Pain Upper: 30 people, 90.91%
Oropharyngeal Pain: 30 people, 90.91%

What are the existing conditions these people have? *

Prostate Cancer: 13 people, 39.39%
Osteoporosis (bones weak and more likely to break): 13 people, 39.39%
High Blood Cholesterol: 11 people, 33.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 6.06%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 6.06%
Stress And Anxiety: 1 person, 3.03%
Nausea (feeling of having an urge to vomit): 1 person, 3.03%
Headache (pain in head): 1 person, 3.03%
Depression: 1 person, 3.03%
Breast Cancer Metastatic: 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Neurontin and have Parathyroid tumor benign?

- Check whether Parathyroid tumor benign is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Neurontin:

Neurontin (107,468 reports)

Browse all side effects of Neurontin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Parathyroid tumor benign:

Parathyroid tumor benign (164 drugs)

Browse all the conditions that are associated with Parathyroid tumor benign:

Parathyroid tumor benign (230 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Neurontin) and Neurontin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.